KLOW vs GLOW: Which Blend to Buy, and When to Pick Separate Vials

Skin, Hair & Tissue Research

KLOW and GLOW share the same three peptides at exactly the same amounts. KLOW adds a fourth, KPV, and that one peptide is the whole KLOW vs GLOW decision. Here is what is in each vial, what the research says about KPV, and which format fits: KLOW, GLOW, the nasal sprays or separate vials.

View product →

Findings

• GLOW is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, 70 mg in total. KLOW is the same three at the same amounts plus 10 mg of KPV, 80 mg in total.
• KPV is Lys-Pro-Val, the last three amino acids of the hormone alpha-MSH. A 2008 review describes it as keeping the parent hormone’s anti-inflammatory activity without its effect on pigment.
• In human intestinal and immune cells, KPV was carried inside by PepT1, a transporter of the gut lining, and nanomolar concentrations damped the NF-kB inflammatory pathway (Gastroenterology, 2008).
• KLOW costs less than GLOW plus a separate KPV vial, and both blends cost less than buying their components as separate vials.

KLOW vs GLOW: what is in each vial

Same core, same strength. The only variable is KPV:

Peptide	GLOW	KLOW
GHK-Cu	50 mg	50 mg
BPC-157	10 mg	10 mg
TB-500	10 mg	10 mg
KPV	None	10 mg
Total	70 mg	80 mg

Each comes two ways: as a lyophilised vial (KLOW Blend, GLOW Blend) or as a ready-mixed nasal spray with the same milligrams per bottle (KLOW Nasal Spray, 10 mL of saline, about 57 sprays; GLOW Nasal Spray, about 57 metered sprays).

So KLOW is not a stronger GLOW. Everything GLOW contains, KLOW contains at the same strength, with KPV on top. The only question is whether KPV belongs in the work, and when in doubt, it does.

KPV: the peptide that decides it

Alpha-MSH is a 13-amino-acid peptide cut from a larger precursor, proopiomelanocortin. It is best known for pigmentation, but it also acts on inflammation: a 2008 review in Endocrine Reviews lists its effects on NF-kB activation, pro-inflammatory cytokines and inflammatory cell migration. Its pigment effect got in the way, and the review describes how its last three amino acids, KPV, kept the anti-inflammatory activity without the pigmentary action. Inflammatory skin and bowel conditions head the review’s list of research directions for KPV.

The gut research is where KPV stands out:

• 2008, how it gets in. In human intestinal epithelial cells and human T cells, KPV entered through PepT1, a di- and tripeptide transporter normally found in the small intestine and induced in the colon during inflammatory bowel disease. Nanomolar concentrations inhibited the NF-kB and MAP kinase signalling pathways and reduced pro-inflammatory cytokine secretion. Given orally, KPV reduced inflammation in two colitis models (Dalmasso et al., Gastroenterology).
• 2008, two more models. A second group reported earlier recovery, fewer inflammatory infiltrates and lower myeloperoxidase activity with KPV in two colitis models, effects that appeared at least partly independent of the melanocortin-1 receptor (Kannengiesser et al., Inflammatory Bowel Diseases).

The shared peptides cover skin, collagen and soft tissue. KPV adds the gut-lining and inflammatory-signalling axis, beside BPC-157, itself native to gastric juice. That pairing is what KLOW gives you and GLOW does not.

The shared core: GHK-Cu, BPC-157 and TB-500

GHK-Cu. GHK (glycyl-histidyl-lysine) was isolated from human plasma and binds copper, which is why both blends have a blue cast. In fibroblast cultures, GHK-Cu stimulated collagen synthesis at picomolar concentrations, peaking at one nanomolar, without any change in cell number (Maquart et al., 1988). A 2015 review notes that GHK is present in plasma, saliva and urine, declines with age, and can up- or down-regulate at least 4,000 human genes.

BPC-157. A 15-amino-acid peptide native to human gastric juice. Two clinic reports from one Florida group stand out: in a 2021 retrospective review, 14 of 16 knee-pain patients reported relief, including 3 of 4 who received BPC-157 together with thymosin beta-4; in a 2024 pilot, 10 of 12 women with interstitial cystitis reported complete resolution of symptoms after a single treatment.

TB-500. Built on thymosin beta-4, a naturally occurring peptide released by platelets, macrophages and many other cells after injury. It binds actin and promotes cell migration, and in wounds it lowers the number of myofibroblasts (Goldstein et al., 2012).

Choose KLOW if

• The work touches the gut lining or inflammatory signalling. KPV is the component with that literature, and BPC-157 sits beside it.
• You want the widest coverage in one vial. KLOW holds everything GLOW does at the same strength, plus KPV. The only thing it rules out is a KPV-free comparison.
• You were going to add KPV to GLOW anyway. The step up from GLOW to KLOW costs less than a KPV vial on its own, and it saves a vial to reconstitute and track.
• You are undecided. KLOW is the default: the same core, one more tool.

Our pick if in doubt: buy KLOW Blend, or the ready-mixed KLOW Nasal Spray.

Choose GLOW if

• The research stays on skin, collagen and soft tissue, and KPV would only be an extra variable.
• You need a KPV-free arm. Run GLOW beside KLOW and the one difference between them is KPV.

Buy GLOW Blend, or the ready-mixed GLOW Nasal Spray.

When separate vials make sense

Both blends are fixed at the same proportions: five parts GHK-Cu to one part of each other peptide. Separate vials are the right call in three cases:

• A different ratio. More KPV or more BPC-157 relative to GHK-Cu, or a ratio that changes between experiments.
• One peptide on its own. A question about a single component is cleanest with that component alone.
• Different schedules. Separate vials can be reconstituted at different times and concentrations.

All four are stocked singly: GHK-Cu, BPC-157, TB-500 and KPV. Bought one by one, the same milligrams cost more than either blend, so separate vials earn their place when the ratio or the isolation matters.

Vial or nasal spray

The vials are lyophilised and reconstituted with bacteriostatic water. The KLOW reconstitution guide, the GLOW reconstitution guide and the peptide calculator cover the arithmetic. The nasal sprays carry the same milligrams per bottle and arrive pre-mixed with sterile saline in a sealed metered atomiser: no reconstitution and no bacteriostatic water needed.

Frequently asked questions

What is the difference between KLOW and GLOW?

One peptide. Both contain 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500. KLOW adds 10 mg of KPV, for 80 mg in total against GLOW’s 70 mg.

What does KPV add to KLOW?

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH, studied in gut-lining and inflammatory-signalling research. In human intestinal and immune cells it entered through the PepT1 transporter and damped NF-kB signalling (Gastroenterology, 2008).

Is KLOW stronger than GLOW?

Not in the shared peptides: GHK-Cu, BPC-157 and TB-500 are at identical amounts in both. KLOW simply carries an extra 10 mg of KPV.

Is KLOW cheaper than buying GLOW and KPV separately?

Yes. KLOW costs less than GLOW plus a separate KPV vial, and both blends cost less than buying their components as separate vials. Current prices are on the product pages.

Where can I buy KLOW and GLOW in Canada?

Vistara Labs supplies KLOW and GLOW as lyophilised vials and as ready-mixed nasal sprays, shipped from within Canada. Laboratory research use only.

Product specifications from vistaralabs.ca, October 2026. Sources: Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008. PMID 18612139. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMID 26236730. Sikiric P et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2018. PMID 29879879. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID 39325560. Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID 22074294.

Related reading: What Is KLOW? The Four-Peptide Blend Explained.

References

No study of the KLOW blend as a complete formulation was identified. The references below cover its individual components.

1. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copperMulder GD et al. · Wound Repair Regen 1994 · PMID 17147644Multicentre randomised, evaluator-blinded, placebo-controlled trial; topical GHK-Cu in diabetic neuropathic ulcers.
2. Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee E et al. · Altern Ther Health Med 2021 · PMID 34324435Retrospective chart review, 17 patients (16 followed up by telephone); no control group, no blinding, no validated outcome instrument.
3. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potentialEsposito S et al. · Drug Test Anal 2012 · PMID 22962027Analytical chemistry: characterises TB-500 as the N-terminally acetylated 17-23 fragment of thymosin β4 (Ac-LKKTETQ), not the intact 43-amino-acid protein.
4. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationDalmasso G et al. · Gastroenterology 2008 · PMID 18061177Laboratory study in human intestinal epithelial cells and human T cells; no human exposure.

Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.